Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda.
Am J Cancer Res. 2012;2(2):130-40. Epub 2012 Feb 15.
Therapeutic choices are limited for undifferentiated metastatic thyroid carcinomas. Although implanted subcutaneous thyroid tumors are standard preclinical models to examine the efficacy of new therapeutic agents, these xenograft models frequently fail to predict the outcomes of clinical trials in patients with metastatic thyroid carcinomas. Genetically engineered mouse models with alterations similar to human cancers in their pathological progression and in an immunocompetent environment offer unparalleled opportunities for evaluating novel potential molecular targets. We review recent advances in the modeling of follicular thyroid carcinoma with distant metastasis and in the use of these mouse models in preclinical studies, emphasizing the significance of genetically engineered mouse models in clinical applications.
对于未分化的转移性甲状腺癌，治疗选择有限。虽然植入皮下的甲状腺肿瘤是标准的临床前模型，用于检查新治疗药物的疗效，但这些异种移植模型经常无法预测转移性甲状腺癌患者临床试验的结果。在具有相似病理进展和免疫能力的环境的遗传工程小鼠模型中，为评估新的潜在分子靶标提供了无与伦比的机会。我们回顾了具有远处转移的滤泡甲状腺癌建模方面的最新进展，以及这些小鼠模型在临床前研究中的应用，强调了遗传工程小鼠模型在临床应用中的重要性。
